DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study of Minirin Melt in Japanese Patients With Central Diabetes Insipidus (CDI).

Information source: Ferring Pharmaceuticals
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Central Diabetes Insipidus

Intervention: Desmopressin Oral Melt (Drug); Desmopressin intranasal (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Ferring Pharmaceuticals

Official(s) and/or principal investigator(s):
Clinical Development Support, Study Director, Affiliation: Ferring Pharmaceuticals

Summary

This is an open-label dose-titration study in Japanese Central Diabetes Insipidus (CDI) patients designed to demonstrate the efficacy and safety of orally-disintegrating tablet of desmopressin.

Clinical Details

Official title: Peroral Administration of Different Doses of Desmopressin Administered as a New Orally-Disintegrating Tablet and Desmopressin for Nasal Administration in the Treatment of CDI in Japanese Patients

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Change from Baseline in 24-hour Urine Volume

Secondary outcome:

24-hour urine volume (mL)

Hourly diuresis rate (mL/hr)

Urine osmolality (mOsm/kg)

Urine specific gravity (g/mL)

Percentage of participants within normal range for urinary output, urinary osmolality and urine specific gravity

Serum sodium level

Participants with Adverse Events Summarized by Incidence and Severity

Eligibility

Minimum age: 6 Years. Maximum age: 75 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Participants must be documented to have Central Diabetes Insipidus (CDI) by at least

two of the following four criteria (a-d): 1. Failure to increase urine osmolality above 300 mOsm/kg during a period of fluid deprivation sufficient to raise plasma osmolality and sodium above the upper limit of normal level for the reference laboratory (usually 295 mOsm/kg and 148 mEq/l, respectively) 2. Complete and continuous control of the DI by desmopressin therapy without "breakthrough" diuresis, hypernatremia, hyponatremia, or symptoms or signs of water intoxication. 3. A deficient plasma vasopressin response to osmotic or non-osmotic stimulation. 4. Absence of the posterior pituitary bright spot on T-1 weighted midsagittal magnetic resonance imaging (MRI) of the brain.

- Given written informed consent prior to any trial-related procedure is performed

- 24 hour urine volume (mL), urine osmolality (mOsm/kg), urine specific gravity, and

serum sodium (mEq/L) maintained at a normal level by desmopressin nasal administration

- Outpatient

- The participant is, in the investigator's opinion, otherwise healthy

- Be willing and able to comply with the protocol requirements including restriction of

water intake Exclusion Criteria:

- Presence or a history of nephrogenic diabetes insipidus or diabetes mellitus

- Presence of uncorrected hypothyroidism, hypoadrenalism or hypogonadism

- Abnormalities or disease of the oral cavity that might affect the release and

absorption of drug

- Unable to be placed on water-intake restriction starting from two hours before

bedtime

- Presence of a hypothalamus abnormality leading to thirst disorder

- Evidence of hepatic, renal, cardiac, or pulmonary dysfunction

- Uncontrolled hypertension

- Treatment with another investigational product within the past 3 months

- Concurrent treatment with diuretics, chlorpropamide, tricyclic antidepressants,

indomethacin, carbamazepine

- Alcohol dependency or drug abuse

- Breastfeeding, pregnant, or likely to become pregnant

- A mental condition, the lack of decision-making ability, dementia or a speech

handicap

- Any other reason that the Investigator believes inappropriate

Locations and Contacts

Osaka Saiseikai Nakatsu Hospital, Osaka, Japan

Saitama Medical Center Jichi Medical University, Saitama, Japan

Aichi Medical University, Nagakute, Aichi, Aichi, Japan

Nagoya University Hospital, Nagoya, Aichi, Japan

Toranomon Hospital, Minato, Tokyo, Japan

Additional Information

Starting date: January 2011
Last updated: August 10, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017